表紙
市場調査レポート

末梢動脈閉塞性疾患(PAOD):パイプライン分析

Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 251608
出版日 ページ情報 英文 236 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
末梢動脈閉塞性疾患(PAOD):パイプライン分析 Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015
出版日: 2015年09月23日 ページ情報: 英文 236 Pages
概要

末梢動脈閉塞性疾患(PAOD)は、心臓と脳の外側に位置する血管(動脈・静脈)の疾患のことを言います。症状には、歩行や階段を登るといった運動の後の股関節、大腿またはふくらはぎの筋肉の痛みを伴うけいれん(間欠性跛行)、脚のしびれまたは衰弱、特にその他の側面と比較した際の下腿または足の冷え、つま先の痛み、治癒しない足または脚、足指の爪の成長の遅さ、および男性の勃起障害(ED)などがあります。

当レポートでは、末梢動脈閉塞性疾患(PAOD)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

末梢動脈閉塞性疾患(PAOD)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Alvogen Korea
  • AnGes MG, Inc.
  • Annexin Pharmaceuticals AB
  • Apceth GmbH & Co. KG
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Betagenon AB
  • Cardiolynx AG
  • CardioVascular BioTherapeutics, Inc.
  • Celgene Corporation
  • Cytokinetics, Inc.
  • Diffusion Pharmaceuticals LLC
  • DNAVEC Corporation
  • Eli Lilly and Company
  • Grifols, S.A.
  • Juventas Therapeutics, Inc.
  • 興和
  • Lacer, S.A.
  • LTT Bio-Pharma Co., Ltd.
  • MedImmune, LLC
  • miRagen Therapeutics, Inc.
  • Multi Gene Vascular Systems Ltd
  • Nuo Therapeutics, Inc.
  • Pluristem Therapeutics Inc.
  • Proteon Therapeutics, Inc.
  • Recardio GmbH
  • RegenoCELL Therapeutics, Inc.
  • Resverlogix Corp.
  • Sagene Pharmaceuticals, Inc.
  • Stemedica Cell Technologies, Inc.
  • Symic Biomedical, Inc.
  • Theravasc, Inc.
  • vasopharm GmbH
  • ViroMed Co., Ltd.
  • Yuyu Pharma, Inc.

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル(製品説明/作用機序/R&D進捗状況)

  • (cilostazol + organic nitrate) ER
  • AEM-28
  • ALD-301
  • Alecmestencel-T
  • Annexin A-5
  • AP-01
  • apabetalone
  • beperminogene perplasmid
  • CVBT-141C
  • DVC1-0101
  • ELS-140
  • evacetrapib
  • 重症虚血肢・末梢動脈閉塞性疾患(PAOD)向け遺伝子治療
  • Human Plasmin
  • JVS-100
  • K-134
  • LA-419
  • LT-0101
  • MEDI-6012
  • 間充織幹細胞
  • MGN-6114
  • MultiGeneAngio
  • MultiGeneGraft
  • MultiStem
  • O-304
  • PDA-002
  • PLX-PAD
  • REC-03
  • rivaroxaban
  • sarpogrelate SR
  • SBCV-030
  • selegiline + Antiplatelet Drugs
  • sodium nitrite SR
  • 循環器系疾患向け幹細胞治療
  • ticagrelor
  • tirasemtiv
  • transcrocetinate sodium
  • TXA-127
  • VAS-2870
  • VM-202
  • vonapanitase
  • YY-984

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7084IDB

Summary

Global Markets Direct's, 'Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H2 2015', provides an overview of the Peripheral Artery Occlusive Disease (PAOD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Peripheral Artery Occlusive Disease (PAOD)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Peripheral Artery Occlusive Disease (PAOD) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Peripheral Artery Occlusive Disease (PAOD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Peripheral Artery Occlusive Disease (PAOD) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Peripheral Artery Occlusive Disease (PAOD)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Peripheral Artery Occlusive Disease (PAOD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Peripheral Artery Occlusive Disease (PAOD) Overview
  • Therapeutics Development
    • Pipeline Products for Peripheral Artery Occlusive Disease (PAOD) - Overview
    • Pipeline Products for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis
  • Peripheral Artery Occlusive Disease (PAOD) - Therapeutics under Development by Companies
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Peripheral Artery Occlusive Disease (PAOD) - Products under Development by Companies
  • Peripheral Artery Occlusive Disease (PAOD) - Companies Involved in Therapeutics Development
    • Alvogen Korea
    • AnGes MG, Inc.
    • Annexin Pharmaceuticals AB
    • Apceth GmbH & Co. KG
    • AstraZeneca Plc
    • Athersys, Inc.
    • Bayer AG
    • Betagenon AB
    • Cardiolynx AG
    • CardioVascular BioTherapeutics, Inc.
    • Celgene Corporation
    • Cytokinetics, Inc.
    • Diffusion Pharmaceuticals LLC
    • DNAVEC Corporation
    • Eli Lilly and Company
    • Grifols, S.A.
    • Juventas Therapeutics, Inc.
    • Kowa Company, Ltd.
    • Lacer, S.A.
    • LTT Bio-Pharma Co., Ltd.
    • MedImmune, LLC
    • miRagen Therapeutics, Inc.
    • Multi Gene Vascular Systems Ltd
    • Nuo Therapeutics, Inc.
    • Pluristem Therapeutics Inc.
    • Proteon Therapeutics, Inc.
    • Recardio GmbH
    • RegenoCELL Therapeutics, Inc.
    • Resverlogix Corp.
    • Sagene Pharmaceuticals, Inc.
    • Stemedica Cell Technologies, Inc.
    • Symic Biomedical, Inc.
    • Theravasc, Inc.
    • vasopharm GmbH
    • ViroMed Co., Ltd.
    • Yuyu Pharma, Inc.
  • Peripheral Artery Occlusive Disease (PAOD) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (cilostazol + organic nitrate) ER - Drug Profile
    • AEM-28 - Drug Profile
    • ALD-301 - Drug Profile
    • Alecmestencel-T - Drug Profile
    • Annexin A-5 - Drug Profile
    • AP-01 - Drug Profile
    • apabetalone - Drug Profile
    • beperminogene perplasmid - Drug Profile
    • CVBT-141C - Drug Profile
    • DVC1-0101 - Drug Profile
    • ELS-140 - Drug Profile
    • evacetrapib - Drug Profile
    • Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile
    • Human Plasmin - Drug Profile
    • JVS-100 - Drug Profile
    • K-134 - Drug Profile
    • LA-419 - Drug Profile
    • LT-0101 - Drug Profile
    • MEDI-6012 - Drug Profile
    • Mesenchymal Stem Cells - Drug Profile
    • MGN-6114 - Drug Profile
    • MultiGeneAngio - Drug Profile
    • MultiGeneGraft - Drug Profile
    • MultiStem - Drug Profile
    • O-304 - Drug Profile
    • PDA-002 - Drug Profile
    • PLX-PAD - Drug Profile
    • REC-03 - Drug Profile
    • rivaroxaban - Drug Profile
    • sarpogrelate SR - Drug Profile
    • SBCV-030 - Drug Profile
    • selegiline + Antiplatelet Drugs - Drug Profile
    • sodium nitrite SR - Drug Profile
    • Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
    • ticagrelor - Drug Profile
    • tirasemtiv - Drug Profile
    • transcrocetinate sodium - Drug Profile
    • TXA-127 - Drug Profile
    • VAS-2870 - Drug Profile
    • VM-202 - Drug Profile
    • vonapanitase - Drug Profile
    • YY-984 - Drug Profile
  • Peripheral Artery Occlusive Disease (PAOD) - Recent Pipeline Updates
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects
  • Peripheral Artery Occlusive Disease (PAOD) - Discontinued Products
  • Peripheral Artery Occlusive Disease (PAOD) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD), H2 2015
  • Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Alvogen Korea, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by AnGes MG, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Annexin Pharmaceuticals AB, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Apceth GmbH & Co. KG, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by AstraZeneca Plc, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Athersys, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Bayer AG, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Betagenon AB, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Cardiolynx AG, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by CardioVascular BioTherapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Celgene Corporation, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Cytokinetics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by DNAVEC Corporation, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Eli Lilly and Company, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Grifols, S.A., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Juventas Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Kowa Company, Ltd., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Lacer, S.A., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by MedImmune, LLC, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by miRagen Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Nuo Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Pluristem Therapeutics Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Proteon Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Recardio GmbH, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by RegenoCELL Therapeutics, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Resverlogix Corp., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Stemedica Cell Technologies, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Symic Biomedical, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Theravasc, Inc., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by vasopharm GmbH, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by ViroMed Co., Ltd., H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Pipeline by Yuyu Pharma, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) Therapeutics - Recent Pipeline Updates, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..1), H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..2), H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..3), H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Dormant Projects (Contd..4), H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Discontinued Products, H2 2015
  • Peripheral Artery Occlusive Disease (PAOD) - Discontinued Products (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD), H2 2015
  • Number of Products under Development for Peripheral Artery Occlusive Disease (PAOD) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top